Newton Charles W.
SEC insider (Form 3/4/5 filer). CIK 0001866219. Director at Keros Therapeutics, Inc. (KROS) and 4 other issuers. 18 reported Form 4/5 transactions since Sep 2024; latest on Aug 18, 2026. Located in LEXINGTON, MA.
Companies Newton Charles W. has filed insider reports for
- Keros Therapeutics, Inc. (KROS): Director
- NOVAVAX INC (NVAX): Director
- Coherus Oncology, Inc. (CHRS): Director
- Lyell Immunopharma, Inc. (LYEL): Officer, Chief Financial Officer
- 2seventy bio, Inc. (TSVT): Director
Newton Charles W.
CIK: 0001866219
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Aug 18, 2026KROS
Keros Therapeutics, Inc.
SaleDirect551 shares at avg. $10.30$6K - Jun 18, 2026NVAX
NOVAVAX INC
AwardDirectRestricted Stock Units
14.2K shares- - Jun 18, 2026NVAX
NOVAVAX INC
AwardDirectStock Option (Right to Buy)
21.3K shares- - Jun 11, 2026KROS
Keros Therapeutics, Inc.
SaleDirect550 shares at avg. $10.04$6K - Jun 5, 2026CHRS
Coherus Oncology, Inc.
AwardDirect30K shares- - Apr 25, 2026NVAX
NOVAVAX INC
ExerciseDirect9.5K shares- - Mar 9, 2026KROS
Keros Therapeutics, Inc.
AwardDirect13.2K shares- - Aug 21, 2025LYEL
Lyell Immunopharma, Inc.
SaleDirect1.5K shares at avg. $10.54$15K - Aug 20, 2025LYEL
Lyell Immunopharma, Inc.
AwardDirect8K shares- - Aug 12, 2025LYEL
Lyell Immunopharma, Inc.
SaleDirect136 shares at avg. $10.34$1K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 |  KROS Keros Therapeutics, Inc. | Sale | 551 | $10.30 | $5,675 | Direct |
| Jun 18, 2026 |  NVAX NOVAVAX INC | Award Restricted Stock Units | 14,180 | - | - | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award Stock Option (Right to Buy) | 21,270 | - | - | Direct |
| Jun 11, 2026 | KROS Keros Therapeutics, Inc. | Sale | 550 | $10.04 | $5,522 | Direct |
| Jun 5, 2026 |  CHRS Coherus Oncology, Inc. | Award | 30,000 | - | $0 | Direct |
| Apr 25, 2026 | NVAX NOVAVAX INC | Exercise | 9,520 | - | $0 | Direct |
| Mar 9, 2026 | KROS Keros Therapeutics, Inc. | Award | 13,215 | - | $0 | Direct |
| Aug 21, 2025 |  LYEL Lyell Immunopharma, Inc. | Sale | 1,453 | $10.54 | $15,320 | Direct |
| Aug 20, 2025 | LYEL Lyell Immunopharma, Inc. | Award | 8,000 | - | - | Direct |
| Aug 12, 2025 | LYEL Lyell Immunopharma, Inc. | Sale | 136 | $10.34 | $1,406 | Direct |
1-10 of 18 transactions